Effect of Amniotic Bladder Therapy on Female Sexual Function of Patients With Interstitial Cystitis/Bladder Pain Syndrome: Early 3-Month Report

Document Type

Article

Publication Date

5-2024

Publication Title

Journal of Gynecologic Surgery

Abstract

Objective: Interstitial cystitis/bladder pain syndrome (IC/BPS) is characterized by many urologic symptoms, including urgency, frequency, and pelvic pain. While 3 of the current authors and other colleagues described the value of micronized amniotic membrane (AM) injection previously to improve lower urinary-tract symptoms in patients with IC/BPS, this study specifically evaluated intradetrusor injections of micronized AM for patients with IC/BPS and concurrent female sexual dysfunction (FSD). Materials and Methods: Eleven consecutive patients with symptoms recalcitrant to multiple other therapies received intradetrusor injections of 100 mg of micronized AM (Clarix Flo® BioTissue, Miami, FL, USA) diluted in 10 mL of 0.9% preservative-free sodium chloride. Results: All patients had severe IC/BPS symptoms at baseline, with an average Interstitial Cystitis Symptoms Index (ICSI) score of 20.9 ± 0.3 and an average Problem Index (ICPI) score of 16 ± 0.0 that decreased to 5.8 ± 1.4 and 4.4 ± 1.4, respectively, at 12 weeks after treatment. Additionally, sexual function, measured by the Female Sexual Function Index (FSFI), improved from 21.2 ± 6.5 to 27.8 ± 6.8 at 12 weeks. This coincided with a reduction of pain associated with intercourse from 8.4 ± 0.9 to 6.3 ± 1.2 at 12 weeks. Conclusions: Amniotic bladder therapy could be a valuable treatment for IC/BPS with FSD, based on these encouraging results at 12 weeks after treatment.

Volume

40

Issue

3

First Page

194

Last Page

199

DOI

10.1089/gyn.2023.00

Link to Full Text

Share

COinS